SUPN Long Call Strategy
SUPN (Supernus Pharmaceuticals, Inc.), in the Healthcare sector, (Drug Manufacturers - Specialty & Generic industry), listed on NASDAQ.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults.
SUPN (Supernus Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a market capitalization of approximately $2.72B, a beta of 0.54 versus the broader market, a 52-week range of 31.16-59.68, average daily share volume of 684K, a public-listing history dating back to 2012, approximately 674 full-time employees. These structural characteristics shape how SUPN stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.54 indicates SUPN has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a long call on SUPN?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current SUPN snapshot
As of June 30, 2026, spot at $46.31, ATM IV 32.50%, IV rank 3.57%, expected move 9.32%. The long call on SUPN below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this long call structure on SUPN specifically: SUPN IV at 32.50% is on the cheap side of its 1-year range, which favors premium-buying structures like a SUPN long call, with a market-implied 1-standard-deviation move of approximately 9.32% (roughly $4.31 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated SUPN expiries trade a higher absolute premium for lower per-day decay. Position sizing on SUPN should anchor to the underlying notional of $46.31 per share and to the trader's directional view on SUPN stock.
SUPN long call setup
The SUPN long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With SUPN near $46.31, the first option leg uses a $46.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed SUPN chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 SUPN shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $46.00 | $1.85 |
SUPN long call risk and reward
- Net Premium / Debit
- -$185.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$185.00
- Breakeven(s)
- $47.85
- Risk / Reward Ratio
- Unbounded
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
SUPN long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on SUPN. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$185.00 |
| $10.25 | -77.9% | -$185.00 |
| $20.49 | -55.8% | -$185.00 |
| $30.72 | -33.7% | -$185.00 |
| $40.96 | -11.5% | -$185.00 |
| $51.20 | +10.6% | +$335.15 |
| $61.44 | +32.7% | +$1,358.97 |
| $71.68 | +54.8% | +$2,382.80 |
| $81.92 | +76.9% | +$3,406.63 |
| $92.15 | +99.0% | +$4,430.46 |
When traders use long call on SUPN
Long calls on SUPN express a bullish thesis with defined risk; traders use them ahead of SUPN catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
SUPN thesis for this long call
The market-implied 1-standard-deviation range for SUPN extends from approximately $42.00 on the downside to $50.62 on the upside. A SUPN long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current SUPN IV rank near 3.57% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on SUPN at 32.50%. As a Healthcare name, SUPN options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to SUPN-specific events.
SUPN long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. SUPN positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move SUPN alongside the broader basket even when SUPN-specific fundamentals are unchanged. Long-premium structures like a long call on SUPN are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current SUPN chain quotes before placing a trade.
Frequently asked questions
- What is a long call on SUPN?
- A long call on SUPN is the long call strategy applied to SUPN (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With SUPN stock trading near $46.31, the strikes shown on this page are snapped to the nearest listed SUPN chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are SUPN long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the SUPN long call priced from the end-of-day chain at a 30-day expiry (ATM IV 32.50%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$185.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a SUPN long call?
- The breakeven for the SUPN long call priced on this page is roughly $47.85 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current SUPN market-implied 1-standard-deviation expected move is approximately 9.32%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on SUPN?
- Long calls on SUPN express a bullish thesis with defined risk; traders use them ahead of SUPN catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current SUPN implied volatility affect this long call?
- SUPN ATM IV is at 32.50% with IV rank near 3.57%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.